Targeting the cell cycle in esophageal adenocarcinoma: An adjunct to anticancer treatment

Medicine and Dentistry

• Therapeutic Procedure 100%
• Cell Cycle 100%
• Esophageal Adenocarcinoma 66%
• Development 33%
• Solid Malignant Neoplasm 33%
• Programmed Cell Death 33%
• Targeted Therapy 33%
• Phosphotransferase 33%
• Exercise 33%
• Man 33%
• Polo-Like Kinase 33%
• Aurora Kinase 33%
• Monotherapy 33%
• Target Cell 33%
• Patient Population 33%
• Cyclin-Dependent Kinase 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Side Effect 66%
• Esophageal Adenocarcinoma 66%
• Solid Malignant Neoplasm 33%
• Phosphotransferase 33%
• Aurora Kinase 33%
• Monotherapy 33%
• Cancer Mortality 33%
• Polo Like Kinase 33%
• Cyclin Dependent Kinase 33%